Wells Fargo has recently initiated Exact Sciences Corp (EXAS) stock to Overweight rating, as announced on August 28, 2024, according to Finviz. Earlier, on June 27, 2024, Scotiabank had initiated the stock to Sector Outperform, setting a price target of $70. Jefferies also resumed Buy rating with a price target of $75. Additionally, The Benchmark Company raised Buy rating on January 2, 2024, with a target price of $91. Guggenheim analysts, in their report published on December 14, 2023, also initiated Buy rating and set a price target of $90 for Exact Sciences Corp’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Exact Sciences Corp (EXAS) Stock Trading Recap
On Friday, Exact Sciences Corp (EXAS) stock saw a modest uptick, ending the day at $71.93 which represents a slight increase of $2.70 or 3.90% from the prior close of $69.23. The stock opened at $69.64 and touched a low of $69.31 during the day, reaching a high of $71.99. The volume of shares traded was 2.95 million exceeding the average volume of 2.47 million.
Sponsored
EXAS Stock Performance and Moving Averages
In recent trading, Exact Sciences Corp (EXAS) stock price has shown some volatility, fluctuating 1.37% over the last five trades and 1.55% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by 18.00%, and it has gained 49.34% in the previous three months. Currently, EXAS is trading at 4.46%, 11.55%, and 22.31% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, EXAS, a Healthcare sector stock, is trading -9.66% below its 52-week high but remains 77.06% above its 52-week low. The Average True Range (ATR) (14 days) of 2.34 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Exact Sciences Corp’s Profitability and Valuation Ratios
Exact Sciences Corp’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of -10.76% and a profit margin of -6.70%, with a gross margin of 18.00%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Exact Sciences Corp’s market capitalization stands at $13.29 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. The forward P/E ratio, which uses projected earnings for the next financial year, is 479.02. Additionally, the Price-to-Sales Ratio is 5.09, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 4.16, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 1.51% of Exact Sciences Corp (EXAS)’s shares, while financial institutions hold 97.36%.
Notable insider trades include Condella Sarah, EVP, Human Resources at Exact Sciences Corp (EXAS), who sold 2000 shares on Apr 01 ’24, at $70 each, totaling $0.14 million. On Mar 28 ’24, Condella Sarah, EVP, Human Resources, sold 2000 shares for $70 each, amounting to $0.14 million. Additionally, on Mar 01 ’24, ORVILLE JACOB A sold 2154 shares at $59.32 each, generating $0.13 million.
